2015 American Transplant Congress
Not Only CD28null But Also CD28pos T Cells Contribute to Rejection During Belatacept Treatment
To explain the underlying immunological mechanisms for rejection under belatacept treatment, the phenotypical and functional characteristics of graft infiltrating lymphocytes were studied during rejection under…2015 American Transplant Congress
Impact of Sirolimus on the Risk of BK Viremia in Simultaneous Pancreas-Kidney Transplant Recipients
BackgroundBK virus (BKV) is a common infection in simultaneous pancreas-kidney (SPK) transplant recipients. Data in kidney transplant recipients suggest that immunosuppression regimens containing an mTORi…2015 American Transplant Congress
Implications of Living Kidney Donor Histology, Volume and Function on Allograft Outcome
Donor factors are determinants of donor quality and therefore graft function in deceased donation (DD). We hypothesized that analogous to DD, donor factors such as…2015 American Transplant Congress
When Do DCD Donors Die? Outcomes and Implications of DCD at a High-Volume, Single-Center OPO in the United States
Introduction: Successful donation (SD) is not always possible following attempted donation after circulatory death (DCD). The goal of this study was to determine the fate…2015 American Transplant Congress
Impact of Early Urinary Tract Infections on Renal Graft Function
Barnes Jewish Hospital, St Louis, MO.
Purpose: Describe the incidence of early urinary tract infections (UTI) after renal transplantation at a large academic transplant center. Evaluate the impact of early UTIs…2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…2015 American Transplant Congress
Retrospective Cohort Study Concerning Efficacy and Safety of Bortezomib in Combination With Or Without Rituximab in Antibody Mediated Rejection in Renal Transplant Recipients
Charité Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany.
Treatment of antibody-mediated rejection (AMR) in renal transplant (tx) patients (pts) is still challenging and long-term outcome remains unsatisfying. Because plasma cells (PCs) are crucial…2015 American Transplant Congress
Angiotensin Receptor Antibody IgG1 Subclass Predicts Accelerated Graft Loss in Those Kidney Transplant Recipients Who Develop Biopsy Proven Transplant Glomerulopathy Irrespective of the Presence Or Absence of Donor Specific Anti HLA Antibodies
We assessed the presence or absence of angiotensin receptor antibodies (ATRab) in all those Kidney Transplant Patients who have had biopsy proven transplant glomerulopathy (TG)…2015 American Transplant Congress
Kidney Allocation Tool of the Future: The Estimated Post-Transplant Survival (EPTS) Score
University of Maryland, Baltimore.
Background:Beginning December 2014, a new kidney transplant allocation system will be used. A component of this system is the Estimated Post-Transplant Survival (EPTS) score, which…2015 American Transplant Congress
A Novel Maintenance Regimen With Calcineurin Inhibitor, MMF and Everolimus Initiated By Dual Induction Therapy With Anti-CD20/25 Antibodies in Renal Transplantation
Surgery III, Tokyo Women's Medical University Hospital, Shinjuku-ku,Tokyo, Japan.
【background】Calcineurin inhibitor (CNI), MMF and steroid has been the gold standard of maintenance regimen in renal transplantation (RTx). A line of new immunosuppressants has emerged…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 170
- Next Page »